What is the official website of Novartis Nederland - Neurologie ?

The official website of Novartis Nederland - Neurologie is http://www.zorgverlener.novartis.nl.

What is Novartis Nederland - Neurologie's cybersecurity risk score?

Novartis Nederland - Neurologie has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Nederland - Neurologie experienced?

According to Rankiteo, Novartis Nederland - Neurologie currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Nederland - Neurologie been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Nederland - Neurologie has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Nederland - Neurologie have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Nederland - Neurologie is not certified under SOC 2 Type 1.

Does Novartis Nederland - Neurologie have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Nederland - Neurologie does not hold a SOC 2 Type 2 certification.

Does Novartis Nederland - Neurologie comply with GDPR ?

According to Rankiteo, Novartis Nederland - Neurologie is not listed as GDPR compliant.

Does Novartis Nederland - Neurologie have PCI DSS certification ?

According to Rankiteo, Novartis Nederland - Neurologie does not currently maintain PCI DSS compliance.

Does Novartis Nederland - Neurologie comply with HIPAA ?

According to Rankiteo, Novartis Nederland - Neurologie is not compliant with HIPAA regulations.

Does Novartis Nederland - Neurologie have ISO 27001 certification ?

According to Rankiteo,Novartis Nederland - Neurologie is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Nederland - Neurologie operate in ?

Novartis Nederland - Neurologie operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Nederland - Neurologie have ?

Novartis Nederland - Neurologie employs approximately None employees people worldwide.

Does Novartis Nederland - Neurologie own any subsidiaries ?

Novartis Nederland - Neurologie presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Nederland - Neurologie have ?

Novartis Nederland - Neurologie's official LinkedIn profile has approximately 2,099 followers.

What is the NAICS classification code for Novartis Nederland - Neurologie ?

Novartis Nederland - Neurologie is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Nederland - Neurologie have a Crunchbase profile ?

No, Novartis Nederland - Neurologie does not have a profile on Crunchbase.

Does Novartis Nederland - Neurologie have a LinkedIn profile ?

Yes, Novartis Nederland - Neurologie maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-nederland-neurologie.

How many cybersecurity incidents has Novartis Nederland - Neurologie experienced ?

As of July 12, 2026, Rankiteo reports that Novartis Nederland - Neurologie has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Nederland - Neurologie have ?

Novartis Nederland - Neurologie has an estimated 5,706 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Nederland - Neurologie faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NNN

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Novartis Nederland - Neurologie Vendor Cyber Rating & Cyber Score

novartis.nl

Add Your Compliance Badge

Novartis heeft een 60-jarige geschiedenis in de neurowetenschappen. We bieden patiënten en artsen een groot assortiment aan geneesmiddelen voor multiple sclerose, de ziekte van Alzheimer, de ziekte van Parkinson, epilepsie, ADHD en migraine. Tevens hebben we producten in de pijplijn voor multiple sclerose, de ziekte van Alzheimer en neuromusculaire therapieën. Om hersenaandoeningen beter te begrijpen en geneesmiddelen met toegevoegde waarde te blijven ontwikkelen voor patiënten wereldwijd, maken we in ons onderzoek gebruik van de nieuwste inzichten in de menselijke genetica, nieuwe beeldvormende technologieën en andere nieuwe benaderingen. De richtlijnen van onze LinkedIn pagina kan je terugvinden op:

NNN A.I CyberSecurity Scoring

Scoring History

NNN

Novartis Nederland - Neurologie CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Nederland ...

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

NNN Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NNN

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Neurologie in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Nederland - Neurologie in 2026.

Incident Types NNN vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Neurologie in 2026.

Incident History - NNN (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Nederland - Neurologie Subsidiaries

NNN

Pharmaceutical Manufacturing

Website: http://www.zorgverlener.novartis.nl

Company Size: 10,001+ employees

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - OncologiePharmaceutical Manufacturing

Novartis Nederland - Cardiovascular, Renal & MetabolismPharmaceutical Manufacturing

Novartis Nederland - DermatologiePharmaceutical Manufacturing

Novartis Nederland - ReumatologiePharmaceutical Manufacturing

Loading…

Novartis Nederland - Neurologie Similar Companies

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Loading…

NEWS

Novartis Nederland - Neurologie CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-58281

SUMMARY

Deserialization of untrusted data in Microsoft Edge (Chromium-based) allows an unauthorized attacker to execute code over a network.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 8.3)

cvss3

Base Score: 8.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:C/C:H/I:H/A:H

Impact Score

Exploitability

1.6

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58281

CVE-2026-10660

SUMMARY

The Bluetooth BAP Broadcast Assistant GATT client in subsys/bluetooth/audio/bap_broadcast_assistant.c reassembled remote Broadcast Receive State data into a single file-static net_buf_simple (att_buf, BT_ATT_MAX_ATTRIBUTE_LEN = 512 bytes) shared by all connection instances, while the BUSY flag, long-read handle, and reset/offset state were per-connection. When the device acts as a Broadcast Assistant connected to multiple Scan Delegator peripherals, notification and long-read callbacks from different connections interleave on the shared buffer: the append in notify_handler (net_buf_simple_add_mem at the not-busy branch) performs no tailroom check, so receive-state notifications from two or more delegators accumulate on the same 512-byte buffer and, with a sufficiently large configured ATT MTU (BT_L2CAP_TX_MTU up to 2000) and two-to-three concurrent connections, write past the buffer into adjacent .bss (net_buf_simple_add only asserts in debug builds). Even below the overflow threshold, one connection's net_buf_simple_reset zeroes the shared length while another connection's reassembly and GATT read offset are in flight, mixing one peer's data into another's parse. A malicious or compromised Scan Delegator (or two colluding peers) over BLE can trigger this, causing out-of-bounds writes (memory corruption / denial of service) and cross-connection data corruption. The fix moves the buffer into the per-connection instance struct so each connection reassembles into its own buffer. Affects Zephyr releases shipping the Broadcast Assistant with the shared buffer, including v4.4.0 and earlier.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 6.4)

cvss3

Base Score: 6.4

Complexity: HIGH

CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

1.6

REFERENCES

CVE-2026-61870

SUMMARY

ImageMagick before 7.1.2-26 contains a memory leak vulnerability in the VIFF encoder when memory allocation fails. Attackers can trigger allocation failures by processing specially crafted VIFF images to exhaust available memory and cause denial of service.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 2.9)

cvss3

Base Score: 2.9

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 2.1

Complexity: HIGH

CVSS:4.0/AV:L/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.4

REFERENCES

CVE-2026-61861

SUMMARY

ImageMagick before 7.1.2-26 contains a use-after-free vulnerability in the FormatMagickCaption method when memory allocation fails. Attackers can trigger memory allocation failures to cause a dangling pointer to reference freed memory, potentially enabling denial of service or code execution.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 6.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-61858

SUMMARY

ImageMagick before 7.1.2-26 contains a policy bypass vulnerability in the APNG encoder and external delegates due to missing validation checks. Attackers can write files to disallowed paths by bypassing configured policy restrictions through the APNG encoding process.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…